Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 1, 2011, Pages 20-29

  Filho, Otto Metzger ^a   Ignatiadis, Michail ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Gene expression profiling; Gene signatures; Histologic grade; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER PROGRAM; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMIC GRADE INDEX; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PROGNOSIS;

EID: 78650309082     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.011     Document Type: Review

References (54)

1. Greenough R.B. Varying degrees of malignancy in cancer of the breast. J Cancer Res 1925, 9:453-462.
2. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636.
3. Patey D.H., Scarff R.W. The position of histology in the prognosis of carcinoma of the breast. Lancet 1928, i:801-804.
4. Bloom H.J. Prognosis in carcinoma of the breast. Br J Cancer 1950, 4:259-288.
5. Bloom H.J. Further studies on prognosis of breast carcinoma. Br J Cancer 1950, 4:347-367.
6. Elston C.W. Pathological aspects of the UK Breast Screening Project with special reference to minimal and 'borderline' lesions. Aust N Z J Surg 1984, 54:201-204.
7. Black M.M., Barclay T.H., Hankey B.F. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 1975, 36:2048-2055.
8. Hartveit F. Prognostic typing in breast cancer. Br Med J 1971, 4:253-257.
9. Bloom H.J., Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11:359-377.
10. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
11. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
12. Haybittle J.L., Blamey R.W., Elston C.W., et al. A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366.
13. Genestie C., Zafrani B., Asselain B., et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res 1998, 18:571-576.
14. Kollias J., Murphy C.A., Elston C.W., et al. The prognosis of small primary breast cancers. Eur J Cancer 1999, 35:908-912.
15. Reed W., Hannisdal E., Boehler P.J., et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000, 88:804-813.
16. Le Doussal V., Tubiana-Hulin M., Friedman S., et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989, 64:1914-1921.
17. Longacre T.A., Ennis M., Quenneville L.A., et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 2006, 19:195-207.
18. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
19. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
20. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006, 354:2463-2472.
21. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
22. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
23. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
24. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.
25. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
26. Eisen M.B., Spellman P.T., Brown P.O., et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
27. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
28. Calza S., Hall P., Auer G., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006, 8:R34.
29. Ihemelandu C.U., Leffall L.D., Dewitty R.L., et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007, 14:2994-3003.
30. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:p96.
31. Yu K., Lee C.H., Tan P.H., et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004, 10:5508-5517.
32. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
33. Sauter G., Lee J., Bartlett J.M., et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333.
34. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst 2009, 101:736-750.
35. Oyama T., Ishikawa Y., Hayashi M., et al. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer 2007, 14:182-188.
36. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246.
37. Liedtke C., Hatzis C., Symmans W.F., et al. Genomic Grade Index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009.
38. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037-1044.
39. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986, 46:2578-2581.
40. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95:681-695.
41. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422.
42. Desmedt C., Haibe-Kains B., Wirapati P., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165.
43. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
44. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
45. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
46. Albain K., Barlow W., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer. Breast Cancer Res Treat 2007, 106.
47. Haibe-Kains B., Desmedt C., Piette F., et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008, 9:394.
48. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214.
49. The NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer (Version 1.2010) © 2009 National Comprehensive Cancer Network, Inc. Available at: NCCN.org [cited].
50. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
51. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
52. Cardoso F., Van't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
53. Sparano J.A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26:721-728.
54. Hornberger J., Cosler L.E., Lyman G.H. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005, 11:313-324.